Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for
patients with advanced hormone-refractory prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Aventis Pharmaceuticals Millennium Pharmaceuticals, Inc.